| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feccd3e88d69dc577d9755c6afbc5cdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6983bfd800a91940f75444b0206cb71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_203f7fb905111dbb86feae8f5ab278c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3e9d77ff72f5282325b4e142dfa5b4c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
1998-08-18^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87dd293a5aabe65025874bee6d2a4afd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dc980b2cf31b125c1509b352bd68319
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9da8cf3186ff7a9fa76771e6f8a188a |
| publicationDate |
1999-03-04^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9910486-A2 |
| titleOfInvention |
Mdm2-specific antisense oligonucleotides |
| abstract |
The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6599741-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1165145-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1165145-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6184212-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7186556-B2 |
| priorityDate |
1997-08-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |